| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Pasireotide |
| Brand | Signifor® |
| Indication | For the treatment of adult patients with Cushing’s Disease for whom surgery is not an option or for whom surgery has failed |
| Assessment Process | |
| Rapid review commissioned | 29/03/2012 |
| Rapid review completed | 10/04/2012 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.